Manage your pharmacy inventory

Deep knowledge on
small-molecule drugs and
the global patents
covering them

Drug patents …
… from Kazakhstan to Kalamazoo

Anticipate generic drug launch

Project your formulary budget

Find generic entry opportunities

BioPharmaceutical Business Intelligence

Uncover prior art in expired and abandoned patents
Obtain formulation and manufacturing information
Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Generated: September 20, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 202179

« Back to Dashboard

NDA 202179 describes PREDNISOLONE SODIUM PHOSPHATE, which is a drug marketed by Vintage, Pharm Assoc, Vintage Pharms, Watson Labs, Alcon Pharms Ltd, Amneal Pharms, Medicis Pharms, Akorn, Edenbridge Pharms, Bausch And Lomb, Sola Barnes Hind, Mylan Pharms Inc, We Pharms, Nesher Pharms, Hi Tech Pharma, Chartwell Rx, Wockhardt, and Mission Pharma, and is included in twenty-eight NDAs. It is available from twenty-one suppliers. Additional details are available on the PREDNISOLONE SODIUM PHOSPHATE profile page.

The generic ingredient in PREDNISOLONE SODIUM PHOSPHATE is prednisolone sodium phosphate. There are eighty-six drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the prednisolone sodium phosphate profile page.

Summary for NDA: 202179

Tradename:	1
Applicant:	1
Ingredient:	1
Patents:	0
Therapeutic Class:	Hormonal Agents, Stimulant/Replacement/Modifying (Adrenal) Inflammatory Bowel Disease Agents Ophthalmic Agents
Formulation / Manufacturing:	see details

Pharmacology for NDA: 202179

Mechanism of Action	Corticosteroid Hormone Receptor Agonists

Suppliers and Packaging for NDA: 202179

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
PREDNISOLONE SODIUM PHOSPHATE	prednisolone sodium phosphate	TABLET, ORALLY DISINTEGRATING;ORAL	202179	ANDA	Mylan Pharmaceuticals Inc.	0378-4710	0378-4710-22	48 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE, PLASTIC (0378-4710-22)
PREDNISOLONE SODIUM PHOSPHATE	prednisolone sodium phosphate	TABLET, ORALLY DISINTEGRATING;ORAL	202179	ANDA	Mylan Pharmaceuticals Inc.	0378-4715	0378-4715-22	48 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE, PLASTIC (0378-4715-22)

Summary for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET, ORALLY DISINTEGRATING;ORAL			Strength	EQ 10MG BASE
Approval Date:	Apr 10, 2013	TE:	AB	RLD:	No

Summary for product number 002

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET, ORALLY DISINTEGRATING;ORAL			Strength	EQ 15MG BASE
Approval Date:	Apr 10, 2013	TE:	AB	RLD:	No

Summary for product number 003

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET, ORALLY DISINTEGRATING;ORAL			Strength	EQ 30MG BASE
Approval Date:	Apr 10, 2013	TE:	AB	RLD:	No

Complete Access Available with Subscription

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.